Navigation Links
President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit


President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.

Proove has been presenting research and data at industry conferences across the country this past year, demonstrating the value and innovation their genetic testing creates in the field of pain medicine. The aim of the conference is to provide attendees with insight from key thought leaders in the industry, and as such, Mr. Meshkin provided an illustrative dialogue on how Proove’s proprietary genetic testing services have been able to assist physicians better understand their patients’ needs based off their genetic profiles.

“It is an incredibly exciting time in healthcare because of the advances the scientific community has been able to achieve with the help of genetic analysis and testing,” stated Meshkin. “Proove Biosciences has been at the front of this industry, providing physicians with the tools and science necessary to better understand the complexities of their patients’ pain, and prescribe treatments that meet their personal needs. The Pain Therapeutics Summit was and ideal medium to illustrate the value that genetic testing can offer in treating and managing patient pain.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michele Rickard Appointed to Vice President- Quality and Continuous Improvement at UAS Labs, The Probiotic Company
2. Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
3. SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President
4. aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research
5. BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
6. Grant Hodgkins, Vice President at USDM Life Sciences, Will Give UDI Presentation at ADA Workshop
7. Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team
8. Bay Area BioEconomy Initiative Appoints Onyx Pharmaceuticals President Pablo Cagnoni to its Steering Committee
9. Dr. Tracy Tsuetaki Joins Parexel As Senior Vice President Of Peri/Post-Approval Services And PAREXEL Consulting
10. Levinson, Dudley Win SPIE Directors’ and President’s Awards
11. Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):